Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct:56:152070.
doi: 10.1016/j.semarthrit.2022.152070. Epub 2022 Jul 14.

FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit

Jason S Kim  1 , Silvana Borges  2 , Daniel J Clauw  3 , Philip G Conaghan  4 , David T Felson  5 , Thomas R Fleming  6 , Rachel Glaser  2 , Elizabeth Hart  2 , Marc Hochberg  7 , Yura Kim  2 , Virginia B Kraus  8 , Larissa Lapteva  2 , Xiaojuan Li  9 , Sharmila Majumdar  10 , Timothy E McAlindon  11 , Ali Mobasheri  12 , Tuhina Neogi  5 , Frank W Roemer  5 , Rebecca Rothwell  2 , Robert Shibuya  2 , Jeffrey Siegel  2 , Lee S Simon  13 , Kurt P Spindler  9 , Nikolay P Nikolov  2
Affiliations
Review

FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit

Jason S Kim et al. Semin Arthritis Rheum. 2022 Oct.

Abstract

Objective: To summarize proceedings of a workshop convened to discuss the current state of science in the disease of osteoarthritis (OA), identify the knowledge gaps, and examine the developmental and regulatory challenges in bringing these products to market.

Design: Summary of the one-day workshop held virtually on June 22nd, 2021.

Results: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA drug development, and the assessment of disease progression and long-term benefit.

Conclusions: Demonstrated by numerous failed clinical trials, OA is a challenging disease for which to develop therapeutics. The challenge is magnified by the slow time of onset of disease and the need for clinical trials of long duration and/or large sample size to demonstrate the effect of an intervention. The OA science community, including academia, pharmaceutical companies, regulatory agencies, and patient communities, must continue to develop and test better clinical endpoints that meaningfully reflect disease modification related to long-term patient benefit.

Keywords: Biomarkers; Clinical benefit; Disease-modifying therapy; Drug development; Long-term benefit; Osteoarthritis; Regulatory approval; Structure-modifying therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest One or more of the authors has received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.

Figures

Fig. 1.
Fig. 1.
Repurposed [19].
See this image and copyright information in PMC

References

    1. Kraus VB, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil 2011;19:515–42. 10.1016/j.joca.2010.08.019. - DOI - PMC - PubMed
    1. Lotz M, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013;72:1756–63. 10.1136/annrheumdis-2013-203726. - DOI - PMC - PubMed
    1. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol 2019;37(Suppl 120):3–6. - PubMed
    1. 21st Century Cures Act, FDA website: 2020. [Accessed 1 June 2022].
    1. FDA-Arthritis Foundation osteoarthritis drug development workshop: assessment of long-term benefit, https://www.fda.gov/drugs/news-events-human-drugs/fda-arthritis-foundati... (2021). - PMC - PubMed

Publication types